Monod Bio, Inc.
Seattle, WA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 700 Dexter Ave N #700, Seattle, WA 98109, USA
- Website
- monod.bio
- Founded
- 2021
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Life Sciences Tools & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Talus Bioscience Inc. | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Virtici LLC | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Institute For Systems Biology | Seattle, WA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Partillion Bioscience Corp | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Triangle Biotechnology, Inc. | Chapel Hill, NC | — |
About the company
Monod Bio, Inc., a Seattle-based biotech company, pursues federal research grants as a prime recipient in the life sciences and biodiagnostics space, operating in the early-stage grant funding model with no federal contracts or contract vehicles in its recent footprint.
Monod Bio's federal activity centers on computational protein design and biosensor development funded by the National Institutes of Health. The vendor holds three prime research grants totaling $998 thousand in obligated dollars across two NIH institutes. The National Institute of General Medical Sciences has funded two awards: an $377 thousand grant awarded August 1, 2026, for design and development of rapid, quantitative biosensors using computational protein design to advance the NovoLISA technology as a faster alternative to traditional ELISAs (performance period ending May 31, 2027); and a $330 thousand award also issued August 1, 2026, under CFDA 93.859 (Biomedical Research and Research Training) for computational protein design of robust and scalable recombinant horseradish peroxidase and poly-HRP reagents intended to replace inconsistent natural-source HRP in diagnostics and research tools (period through July 31, 2027). The National Center for Advancing Translational Sciences awarded a $290 thousand grant dated January 1, 2024, completing December 31, 2025, for development of a novel endotoxin biosensor using bioluminescent detection to replace horseshoe crab-derived Limulus amebocyte lysate assays in pharmaceutical and medical device testing. All work is performed in Seattle, Washington. Monod Bio operates as a 100% prime recipient with no reported subcontractor role in recent activity. Two awards face ultimate completion within the next twenty-four months, positioning the vendor for potential follow-on funding or recompete in 2025–2027. The vendor's grant footprint reflects early-stage biotech innovation funding rather than services contracting or large-scale program delivery.
Quick answers
Is Monod Bio, Inc. registered in SAM.gov?
Yes. Monod Bio, Inc.'s SAM.gov registration is active through September 10, 2027.
What is Monod Bio, Inc.'s CAGE code?
Monod Bio, Inc.'s CAGE code is 9RW15, and its Unique Entity ID (UEI) is LB2HDKKRL463.
What is Monod Bio, Inc.'s most recent federal award?
Monod Bio, Inc.'s most recent federal grant award is Design of rapid and quantitative biosensors with computational protein design (R44GM161195), from National Institute of General Medical Sciences (NIH), on August 1, 2026.
On GovTribe
See Monod Bio, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors